SESara M. Eltabey

Sara M. Eltabey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara M. Eltabey has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach

    by Sara M. Eltabey, Ali H. Ibrahim, Mahmoud M. Zaky, Adel Ehab Ibrahim, Yahya Bin Abdullah Alrashdi, Sami El Deeb, Moustafa M. Saleh

    The spread of multidrug-resistant Escherichia coli in healthcare facilities is a global challenge. Hospital-acquired infections produced by Escherichia coli include gastrointestinal, blood-borne, urinary tract, surgical sites, and neonatal infections. Therefore, novel approaches are needed to deal with this pathogen and its rising resistance. The concept of attenuating virulence factors is an alternative strategy that might lead to low levels of resistance and combat this pathogen. A sub-inhibitory concentration (¼ MIC) of sitagliptin and nitazoxanide was used for phenotypic assessments of Escherichia coli virulence factors such as biofilm production, swimming motility, serum resistance, and protease production. Moreover, qRT-PCR was used to determine the impact of sub-MIC of the tested drugs on the relative expression levels of papC, fimH, fliC, kpsMTII, ompT_m, and stcE genes encoding virulence factors in Escherichia coli. Also, an in vivo model was conducted as a confirmatory test. Phenotypically, our findings demonstrated that the tested strains showed a significant decrease in all the tested virulence factors. Moreover, the genotypic results showed a significant downregulation in the relative expression levels of all the tested genes. Besides, the examined drugs were found to be effective in protecting mice against Escherichia coli pathogenesis. Sitagliptin and nitazoxanide exhibited strong anti-virulence activities against Escherichia coli. In addition, it is recommended that they might function as adjuvant in the management of Escherichia coli infections with either conventional antimicrobial agents or alone as alternative treatment measures.


  • Open Access

    The Promising Effect of Ascorbic Acid and Paracetamol as Anti-Biofilm and Anti-Virulence Agents against Resistant Escherichia coli

    by Sara M. Eltabey, Ali H. Ibrahim, Mahmoud M. Zaky, Adel Ehab Ibrahim, Yahya Bin Abdullah Alrashdi, Sami El Deeb, Moustafa M. Saleh

    Escherichia coli is a major cause of serious infections, with antibiotic resistance rendering many treatments ineffective. Hence, novel strategies to combat this pathogen are needed. Anti-virulence therapy is a promising new approach for the subsequent era. Recent research has examined the impact of sub-inhibitory doses of ascorbic acid and paracetamol on Escherichia coli virulence factors. This study evaluated biofilm formation, protease production, motility behavior, serum resistance, expression of virulence-regulating genes (using RT-PCR), and survival rates in a mouse model. Ascorbic acid significantly reduced biofilm formation, protease production, motility, and serum resistance from 100% in untreated isolates to 22–89%, 10–89%, 2–57%, and 31–35% in treated isolates, respectively. Paracetamol also reduced these factors from 100% in untreated isolates to 16–76%, 1–43%, 16–38%, and 31–35%, respectively. Both drugs significantly down-regulated virulence-regulating genes papC, fimH, ompT_m, stcE, fliC, and kpsMTII. Mice treated with these drugs had a 100% survival rate compared with 60% in the positive control group control inoculated with untreated bacteria. This study highlights the potential of ascorbic acid and paracetamol as anti-virulence agents, suggesting their use as adjunct therapies alongside conventional antimicrobials or as alternative treatments for resistant Escherichia coli infections.


  • Open Access

    Anti-virulence as a Novel Strategy for Combating Multi-drug Resistant Escherichia coli

    by Sara M. Eltabey, Ali H. Ibrahim, Mahmoud M. Zaky, Moustafa M. Saleh

    Escherichia coli is a Gram-negative bacterium that has the potential to be either harmful or beneficial as a foodborne pathogen, nosocomial organism, or part of the normal microbiota. It is one of the most prevalent nosocomial pathogens in the human population and is a life-threatening risk. Escherichia coli is the primary causative agent of urinary tract infections, gastrointestinal tract infections, pneumonia, surgical site infections, hemolytic uremic syndrome, sepsis, and neonatal meningitis. The production of virulence factors such as biofilm, motility, serum resistance, and protease enzymes by Escherichia coli contributes to its pathogenicity. The emergence of multi-drug resistant strains of Escherichia coli, due to the inappropriate use of antimicrobial agents, has made treatment challenging. Infectious diseases stemming from antimicrobial-resistant Escherichia coli represent a menace to global health, carrying significant social and economic implications. Antivirulence therapy presents a promising approach to combat microbial infections. This strategy revolves around disarming microbial pathogens by diminishing the production of virulence factors and eradicating their ability to harm the host. It is foreseen that anti-virulence agents could address infections caused by multi-drug resistant Escherichia coli, either as supplementary or as substitutes for traditional antibiotics.

  • Open Access

    Mitigation of Virulence in Resistant Escherichia Coli by Diclofenac Sodium, Phenotypic and Genotypic Study.

    by Sara M. Eltabey, Ali H. Ibrahim, Mahmoud M. Zaky, Moustafa M. Saleh

    Escherichia coli is one of the most ubiquitous pathogens causing several life-threatening diseases. Currently, antibiotics are failing fast while rates of drug-resistant bacteria are increasing worldwide with almost no new drugs coming to market and even last-resort antibiotics are becoming ineffective. Anti-virulence is a new approach targeting bacterial virulence and unlike classic antibiotics is aimed at disarming pathogens rather than killing them or inhibiting their growth. Inactivation of the bacterial arsenal of virulence factors will attenuate pathogens and render them susceptible to natural host defenses. The effect of the FDA-approved drug diclofenac sodium at a sub-inhibitory concentration (¼ MIC) on some Escherichia coli virulence factors was evaluated phenotypically and genotypically. Phenotypically, biofilm formation ability, proteases production and motility behavior were found to be significantly decreased under the effect of diclofenac sodium. Genotypically, qRT-PCR was used to evaluate the relative expression levels of papC, fimH, ompT_m, stcE and flic genes regulating virulence factors production. Importantly, the relative expression levels of all the tested genes showed significant downregulation under the effect of diclofenac sodium. The current research revealed that diclofenac sodium has a promising anti-virulence effect against resistant Escherichia coli. As a result, it is suggested that, in addition to or as an adjuvant to traditional antimicrobials, diclofenac sodium could be a possible solution to treat infections caused by resistant Escherichia coli.